Automated bone marrow cell classification using ensemble learning: performance, generalization, and clinical interpretability - Top-Institutions - MDSpire

Automated bone marrow cell classification using ensemble learning: performance, generalization, and clinical interpretability

  • By

  • Shahid Mehmood

  • Muhammad Zubair

  • Sagheer Abbas

  • Rowida Mohammed Alharbi

  • Mai Alduailij

  • Muhammad Adnan Khan

  • Taher M. Ghazal

  • June 3, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    UCSF Helen Diller Family Comprehensive Cancer Center
    UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

    Key Differentiators

    • Hematology
    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    Hospital Clínico of Valencia
    Hospital Clínico of Valencia

    Valencia, Spain

    Key Differentiators

    • Hematology

  • #4

    European Society for Blood and Marrow Transplantation (EBMT)
    European Society for Blood and Marrow Transplantation (EBMT)

    N/A, N/A

    Key Differentiators

    • Hematology
    • Transplantation

  • #5

    Ludwig Maximilian University
    Ludwig Maximilian University

    Munich, Germany

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

Automated bone marrow cell classification using ensemble learning: performance, generalization, and clinical interpretability

  • by Shahid Mehmood, Muhammad Zubair, Sagheer Abbas, Rowida Mohammed Alharbi, Mai Alduailij, Muhammad Adnan Khan, Taher M. Ghazal

  • June 3, 2026

Related Content

Target receptor expression dictates the selective intra-tumoral targeting of CD8+ T cells by eciskafusp alfa in matched PBMCs and TILs from CPI-naïve patients

Multimodal feature fusion model for breast mass malignant risk stratification

Case series analysis of immunophenotypic evolution during recurrence of low-grade endometrial stromal sarcoma: implications for molecular stability and clinical management